DT
Defence Therapeutics Inc.
DTCFF · OTC
$0.34 +0.78% (+$0.00)
1M -4.45%
Market Cap $36.2M
P/E Ratio -
Div. Yield -
ROE 1,379.11%
Bulios Fair Price
$0.27
21.5% downside
Current Price
$0.34
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DTCFF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
17 /100
Expensive P/B 6.67x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 1,379.11%
ROA 65.40%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 3.37x
Int. coverage -19.19x
Debt/Equity 0.29x
Stability
18 /100
Unstable EPS volatility 88.26%
Profitable years 0
Beta 1.35x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DTCFF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amie Phinney
Employees
1,300
Headquarters
Montreal